Agenus On Saturday Announced Botensilimab/Balstilimab Combination Delivers Durable Responses Across Multiple Sarcoma Subtypes
Portfolio Pulse from Charles Gross
Agenus Inc. (NASDAQ:AGEN) announced expanded data from its phase 1b study of botensilimab and balstilimab in patients with advanced sarcomas. The results showed a 40% 6-month PFS, 20% ORR, and a 63% disease control rate. The median duration of response was 19.4 months.
October 22, 2023 | 3:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Agenus Inc.'s phase 1b study results of botensilimab and balstilimab show promising results in treating advanced sarcomas, which could potentially boost the company's stock.
The positive results from the phase 1b study of botensilimab and balstilimab in treating advanced sarcomas indicate a potential new revenue stream for Agenus Inc. This could attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100